{"id":"NCT00387881","sponsor":"GlaxoSmithKline","briefTitle":"TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Tolerability of TREXIMA* (Sumatriptan Succinate/Naproxen Sodium) for a Single Moderate or Severe Headache in Adults Diagnosed With Probable Migraine Without Aura (ICHD-II 1.6.1) (*TREXIMET)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2008-02","completion":"2008-02","firstPosted":"2006-10-13","resultsPosted":"2009-07-10","lastUpdate":"2016-12-16"},"enrollment":679,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine, Without Aura"],"interventions":[{"type":"DRUG","name":"sumatriptan succinate / naproxen sodium","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Treximet","type":"EXPERIMENTAL"}],"summary":"This study was designed to determine the efficacy and tolerability of TREXIMET (formerly known as TREXIMA) compared to placebo for the acute treatment of probable migraine, a sub-type of migraine.","primaryOutcome":{"measure":"Pain-Free at 2 Hours Post-dose and Sustained Pain-Free From 2-24 Hours Post-dose.","timeFrame":"2 hours through 24 hours after Treatment","effectByArm":[{"arm":"Placebo","deltaMin":25,"sd":null},{"arm":"Sumatriptan/Naproxen","deltaMin":64,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":12},"locations":{"siteCount":70,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":246},"commonTop":[]}}